Hem › Burkitts lymfom › Texas › Houston
Kliniska studier för Burkitts lymfom i Houston, TX
21 studier för Burkitts lymfom söker deltagare vid platser i och runt Houston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
RekryterarFas 3
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
RekryterarFas 3
- Houston Methodist Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekryterarObservationsstudie
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekryterarFas 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
RekryterarFas 3
- The University of Texas MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekryterarFas 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RekryterarFas 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekryterarFas 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
RekryterarFas 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
RekryterarFas 2
- Baylor Texas Children's Hospital, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
RekryterarFas 2
- M D Anderson Cancer Center, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
RekryterarFas 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekryterarFas 1/2
- University of Texas MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
RekryterarFas 1/2
- M D Anderson Cancer Center, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
RekryterarFas 1/2
- Research Site, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
RekryterarFas 2
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RekryterarFas 1
- University of Texas MD Anderson Cancer Center, Houston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RekryterarFas 1/2
- MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
RekryterarFas 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekryterarFas 1
- MD Anderson Cancer Center, Houston
Burkitts lymfom-studier i andra städer
- Philadelphia, PA16 studier
- Milwaukee, WI16 studier
- Chicago, IL15 studier
- Cincinnati, OH13 studier
- New York City, NY13 studier
- Atlanta, GA12 studier
- Aurora, CO11 studier
- Seattle, WA11 studier
- Durham, NC10 studier
- Boston, MA10 studier
- Kansas City, MO10 studier
- Los Angeles, CA10 studier
Andra studier i Houston
- Icke-småcellig lungcancer145 studier
- Bröstcancer126 studier
- Cancer (alla typer)121 studier
- Metastaserande cancer104 studier
- Kolorektal cancer102 studier
- Äggstockscancer89 studier
- Akut myeloid leukemi85 studier
- Lungcancer78 studier
- Prostatacancer76 studier
- Endometriecancer68 studier
- Bukspottkörtelcancer61 studier
- Melanom59 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.